CN114907311A - 一种基于aie性能的脂滴特异性荧光探针及制备方法和应用 - Google Patents
一种基于aie性能的脂滴特异性荧光探针及制备方法和应用 Download PDFInfo
- Publication number
- CN114907311A CN114907311A CN202210541590.3A CN202210541590A CN114907311A CN 114907311 A CN114907311 A CN 114907311A CN 202210541590 A CN202210541590 A CN 202210541590A CN 114907311 A CN114907311 A CN 114907311A
- Authority
- CN
- China
- Prior art keywords
- fluorescent probe
- tdti
- lipid droplet
- aie
- specific fluorescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 42
- 150000002632 lipids Chemical class 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 61
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 238000003384 imaging method Methods 0.000 claims abstract description 18
- 241000252212 Danio rerio Species 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 6
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 22
- 239000011259 mixed solution Substances 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 18
- 238000010992 reflux Methods 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- UHKAJLSKXBADFT-UHFFFAOYSA-N 1,3-indandione Chemical compound C1=CC=C2C(=O)CC(=O)C2=C1 UHKAJLSKXBADFT-UHFFFAOYSA-N 0.000 claims description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- -1 5-bromo-2, 2-bithiophene formaldehyde Chemical compound 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 8
- TWWQCBRELPOMER-UHFFFAOYSA-N [4-(n-phenylanilino)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 TWWQCBRELPOMER-UHFFFAOYSA-N 0.000 claims description 7
- 238000004440 column chromatography Methods 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 2
- 239000012074 organic phase Substances 0.000 claims description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 abstract description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 9
- 239000001301 oxygen Substances 0.000 abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 abstract description 9
- 230000002776 aggregation Effects 0.000 abstract description 7
- 238000004220 aggregation Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 206010034972 Photosensitivity reaction Diseases 0.000 abstract description 4
- 208000007578 phototoxic dermatitis Diseases 0.000 abstract description 4
- 231100000018 phototoxicity Toxicity 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 12
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 10
- 239000005642 Oleic acid Substances 0.000 description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 238000002189 fluorescence spectrum Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 238000001209 resonance light scattering Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 230000008832 photodamage Effects 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000007614 solvation Methods 0.000 description 3
- 238000012984 biological imaging Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000006617 triphenylamine group Chemical group 0.000 description 2
- OHZAHWOAMVVGEL-UHFFFAOYSA-N 2,2'-bithiophene Chemical group C1=CSC(C=2SC=CC=2)=C1 OHZAHWOAMVVGEL-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ODHXBMXNKOYIBV-UHFFFAOYSA-N triphenylamine Chemical compound C1=CC=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 ODHXBMXNKOYIBV-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1011—Condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1014—Carbocyclic compounds bridged by heteroatoms, e.g. N, P, Si or B
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1092—Heterocyclic compounds characterised by ligands containing sulfur as the only heteroatom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于聚集诱导发光(AIE)的荧光探针技术领域,公开了一种基于AIE性能的脂滴特异性荧光探针及制备方法和应用。通过本发明方法制备得到具有AIE性能的荧光探针,分子式为C36H23NO2S2。其合成简单,聚集状态下有较强的红光发射。此外,探针分子具有优异的光稳定性,可特异性靶向LD,并且实现了癌细胞与正常细胞的区分,对LD的动态追踪以及活体斑马鱼中LD的特异性成像。更重要的是,探针分子在白光照射下能够有效的产生活性氧,对癌细胞具有一定的光毒性,在肿瘤细胞光动力治疗方面有潜在的应用。
Description
技术领域
本发明属于聚集诱导发光(AIE)的荧光探针技术领域,具体涉及一种基于AIE性能的脂滴特异性荧光探针及制备方法和应用。
背景技术
脂滴(LD)是由中性脂核及载有相关蛋白的单层磷脂组成的细胞器,除了可用于能量储存外,还参与细胞活化、迁移、增殖和细胞凋亡等生理过程。LD数量增多在II型糖尿病、肥胖症和动脉粥样硬化等疾病中都能够被检测到。特别是,由于癌细胞代谢活动的改变,癌细胞中LD的数量远多于正常细胞,这使得LD可以作为一种癌症诊断的标志物。因此,对细胞中LD的监测具有重要的研究意义。
荧光探针由于灵敏度高、非侵入性,易操作等优点已成为监测LD的主要手段。相比已报道的大多数短波长LD特异性荧光探针,能够聚焦激发并减少自体荧光的红光发射荧光探针具有低光损伤和高分辨率成像的优点。另外,大多数传统的有机荧光探针不可避免的面临“聚集诱导猝灭”(ACQ)这一问题,而“聚集诱导发射”(AIE)特性的荧光探针具有高亮度、高光稳定性和大的Stokes位移等优点。因此,开发具有红光发射、AIE性能且能特异性靶向LD的荧光探针并探索其在生物成像方面的应用越来越受到人们关注。
发明内容
针对上述问题本发明提供了一种基于AIE性能的脂滴特异性荧光探针及制备方法和应用。以三苯胺、联噻吩单元和1,3-茚满二酮基团分别作为电子给体(D)、π桥和电子受体(A)设计合成了具有D-π-A结构的有机小分子荧光探针TDTI。在TDTI的溶液中由于分子内C-C单键的自由旋转消耗了激发态的能量,其表现出极其微弱的荧光。然而,在固态或聚集状态下由于非辐射跃迁损耗能量的过程受到限制,观察到明亮的近红外(682nm)荧光发射。此外,TDTI具有优异的光稳定性,可作为亲脂性荧光探针用于高特异性靶向LD,实现癌细胞与正常细胞的区分,高保真地追踪活细胞中LD的动态特征以及活体斑马鱼中LD的特异性成像。在白光照射下,其PBS溶液中能够产生活性氧,并且有、无白光照射的MTT实验对照验证了TDTI对癌细胞的光毒性,这表明其在肿瘤细胞光动力治疗方面有潜在的应用前景。
为了达到上述目的,本发明采用了下列技术方案:
本发明提供例一种基于AIE性能的脂滴特异性荧光探针,所述荧光探针的分子式为C36H23NO2S2,结构式为:
本发明提供了一种上述荧光探针的制备方法:包括以下步骤:
步骤1:将4-(二苯基氨基)苯基硼酸、5-溴-2,2-联噻吩甲醛和四三苯基磷钯溶解在由1,4-二氧六环和碳酸钠水溶液组成的混合溶液中,于氮气氛围中持续搅拌加热回流,反应完成后,冷却至室温,过滤,收集得到的滤液,经过萃取、洗涤后,收集有机相,干燥、旋干,经柱色谱纯化得到化合物5-(4-(二苯基氨基)苯基)联噻吩-2-甲醛(TPA-TTA);
步骤2:将步骤1中得到的化合物5-(4-(二苯基氨基)苯基)联噻吩-2-甲醛和1,3-茚满二酮溶于由甲醇和甲苯组成的混合溶液中,滴加哌啶,持续搅拌加热回流,反应完成后,冷却至室温,过滤、洗涤得到目标固体化合物,即为所述的荧光探针。
进一步,所述步骤1中5-溴-2,2-联噻吩甲醛:4-(二苯基氨基)苯基硼酸:四三苯基磷钯的摩尔比为1:0.9~1.1:0.055;由1,4-二氧六环和碳酸钠水溶液组成的混合溶液中1,4-二氧六环和碳酸钠水溶液的体积比为3:1;碳酸钠水溶液的浓度为1.5-3mmol;每1mmol5-溴-2,2-联噻吩甲醛使用混合溶液16mL。
所述步骤1中搅拌加热回流的搅拌转速为600-750rpm,加热回流时间为20~22h;萃取用二氯甲烷,三次;洗涤用饱和食盐水,两次;干燥用无水Na2(SO4);柱色谱纯化的展开剂为乙酸乙酯:石油醚=1:5,v/v。
所述步骤2中5-(4-(二苯基氨基)苯基)联噻吩-2-甲醛、1,3-茚满二酮和哌啶的摩尔比为1.5~3.5:6:3.5;由甲醇和甲苯组成的混合溶液中甲醇和甲苯的体积比为1:2;每1mmol 1,3-茚满二酮用混合溶液20mL。
所述步骤2中搅拌加热回流的搅拌转速为600-750rpm,加热回流时间为19~21h;洗涤用冷乙醇,乙腈反复洗涤;
本发明提供了一种上述荧光探针的应用,用于制备动态追踪LD的试剂或识别癌细胞的试剂。
本发明又提供了一种上述荧光探针的应用,制备用于活体斑马鱼中LD特异性成像的试剂。
本发明还提供了一种上述荧光探针的应用,用于制备肿瘤细胞光动力治疗的试剂。
与现有技术相比本发明具有以下优点:
1、本发明基于三苯胺基团具有AIE性能的LD特异性荧光探针TDTI合成较易,只需两步就可以完成,且后处理过程简单。
2、本发明荧光探针分子TDTI具有可见光区的激发和红光发射,降低了对细胞组织的光损伤,并提高了其穿透能力。
3、本发明荧光探针分子TDTI用于生物成像,具有优异的光稳定性,能够高特异性地靶向LD,实现了癌细胞与正常细胞的区分,高保真地追踪活细胞中LD的动态特征以及活体斑马鱼中LD的特异性成像。更进一步,本发明探针TDTI光敏产生活性氧的能力,使其对癌细胞具有光毒性,在肿瘤细胞光动力治疗方面有潜在的应用前景。
附图说明
图1为本发明探针TDTI在不同极性溶剂中的紫外吸收和荧光光谱示意图;其中:(a)为TDTI在不同极性溶剂中的紫外吸收示意图;(b)为TDTI的荧光光谱随不同比例的1,4-二氧六环/H2O变化示意图;(c)为TDTI在不同极性溶剂中的归一化荧光光谱示意图。
图2(a)为探针TDTI在不同体积比的DMSO/甲苯混合溶液中的荧光光谱示意图;(b)为探针TDTI在其良溶剂DMSO和不良溶剂水、甲苯中,放大400倍的光学显微成像示意图;(c)为探针TDTI在不同体积比的DMSO/甲苯混合溶液中的荧光共振光散射(RLS)光谱示意图;(d)为TDTI的固体荧光光谱示意图。
图3(a)为探针TDTI在H2O、油酸中的荧光光谱示意图;(b)为TDTI在PBS溶液、含DMPC(40μg/mL)的PBS溶液和含DMPC和TAG(80μg/mL)的PBS溶液中的荧光光谱示意图。
图4为探针分子TDTI与商业化LD染料BODIPY493/503分子在HeLa细胞中的共定位示意图;其中:(a)为TDTI的红色荧光通道;(b)为BODIPY493/503的绿色荧光通道;(c)为TDTI与BODIPY493/503复合场的叠合;(d)为散点图。条件:(a)λex=514nm和λem=550-700nm,(b)λex=488nm和λem=500-540nm。
图5为癌细胞和正常细胞与TP-DCYP(15μM)孵育4.5h后的荧光成像示意图;其中:(a-c)为癌细胞成像的荧光通道;(g-i)为癌细胞成像的叠合场;(d-f)为正常细胞成像的荧光通道;(j-l)为正常细胞成像的叠合场。
图6为油酸(50μM)处理和未经油酸处理的HeLa细胞与正常细胞LO2继续用TDTI(15μM)孵育的荧光成像示意图;其中无油酸处理:LO2细胞(a)为荧光通道;(b)为叠合场;HeLa细胞(c)为荧光通道;(d)为叠合场;油酸处理LO2细胞(e)荧为光通道;(f)为叠合场;HeLa细胞(g)为荧光通道;(h)为叠合场。
图7为用不同伪彩标记HeLa细胞中的LD在不同时间点的荧光成像及其叠合成像示意图。
图8为斑马鱼的荧光成像示意图;其中空白对照(a)为荧光通道;(b)为叠合场;TDTI(15μM)孵育5h,(c)为荧光通道;(d)为叠合场。
图9为DCFH-DA(10μM)的荧光光谱示意图;其中(a)为白光照射不同时间;(b)为加入TDTI(10μM)白光照射不同时间;(c)为加入TDTI(10μM)以及抗坏血酸AA(1mM)白光照射不同时间;(d)为分别在AA(1mM)和TDTI(10μM)共同存在、仅有TDTI(10μM)存在下有/无光照。
图10为不同浓度的TDTI孵育的HEPG2细胞在有无白光照射下的存活率示意图。
图11为本发明探针分子TDTI的合成路线。
具体实施方式
下面结合本发明实施例和附图,对本发明实施例中的技术方案进行具体、详细的说明。应当指出,对于本领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干变型和改进,这些也应视为属于本发明的保护范围。
实施例1
制备荧光探针TDTI的原料TPA-TTA的合成:在装有磁力搅拌器的25mL三口瓶中,先分别加入4-(二苯基氨基)苯硼酸(1.1mmol,0.318g),5-溴-2,2-联噻吩甲醛(1mmol,0.273g)和四三苯基磷钯(0.055mmol,0.06g),再加入12mL的1,4-二氧六环,4mL的碳酸钠水溶液(2mmol),将混合物经氮气保护持续加热回流搅拌(600rpm)21小时。通过TLC确认反应完成后,将混合物冷却至室温,将反应液过滤后用二氯甲烷萃取三次,饱和食盐水洗涤两次,无水Na2SO4干燥,减压除去溶剂,并通过柱色谱法(乙酸乙酯/石油醚,1/5,v/v)进一步纯化产物,得到橙色固体化合物TPA-TTA(0.329g,75.2%)。
实施例2
制备荧光探针TDTI的原料TPA-TTA的合成:在装有磁力搅拌器的25mL三口瓶中,先分别加入4-(二苯基氨基)苯硼酸(1mmol,0.289g),5-溴-2,2-联噻吩甲醛(1mmol,0.273g)和四三苯基磷钯(0.055mmol,0.06g),再加入12mL的1,4-二氧六环,4mL的碳酸钠水溶液(1.5mmol),将混合物经氮气保护持续加热回流搅拌(650rpm)20小时。通过TLC确认反应完成后,将混合物冷却至室温,将反应液过滤后用二氯甲烷萃取三次,饱和食盐水洗涤两次,无水Na2SO4干燥,减压除去溶剂,并通过柱色谱法(乙酸乙酯/石油醚,1/5,v/v)进一步纯化产物,得到橙色固体化合物TPA-TTA(0.308g,70.3%)。
实施例3
制备荧光探针TDTI的原料TPA-TTA的合成:在装有磁力搅拌器的25mL三口瓶中,先分别加入4-(二苯基氨基)苯硼酸(0.9mmol,0.260g),5-溴-2,2-联噻吩甲醛(1mmol,0.273g)和四三苯基磷钯(0.055mmol,0.06g),再加入12mL的1,4-二氧六环,4mL的碳酸钠水溶液(3mmol),将混合物经氮气保护持续加热回流搅拌(750rpm)22小时。通过TLC确认反应完成后,将混合物冷却至室温,将反应液过滤后用二氯甲烷萃取三次,饱和食盐水洗涤两次,无水Na2SO4干燥,减压除去溶剂,并通过柱色谱法(乙酸乙酯/石油醚,1/5,v/v)进一步纯化产物,得到橙色固体化合物TPA-TTA(0.256g,64.8%)。
实施例4
荧光探针分子TDTI的合成:在装有磁力搅拌器的25mL三口瓶中,将TPA-TTA(0.25mmol,0.108g)和1,3-茚满二酮(0.60mmol,0.088g)溶于12mL甲醇和甲苯(1/2,v/v)的混合溶液中,并滴加35μL的哌啶,持续搅拌(650rpm)加热回流20h,通过TLC确认反应完成后,将冷却至室温的混合物过滤,用冷乙醇,乙腈洗涤得到目标红色固体化合物TDTI(0.064g,45.2%)。
1H NMR(600MHz,CDCl3)δ7.94(d,J=24.4Hz,3H),7.86(s,1H),7.77(s,2H),7.47(m,3H),7.30(d,J=17.0Hz,2H),7.21(s,1H),7.15(d,J=5.6Hz,4H),7.09(s,4H).13C NMR(600MHz,CDCl3)δ190.2,189.7,150.6,148.0,147.3,146.7,143.7,142.0,140.5,134.5,129.4,127.6,127.1,126.6,124.9,124.4,123.5,123.4,123.1,122.9,122.7.MS(ESI)calcd for C36H23NO2S2[M+H]+,566.1204;found566.1234.
实施例5
荧光探针分子TDTI的合成:在装有磁力搅拌器的25mL三口瓶中,将TPA-TTA(0.15mmol,0.065g)和1,3-茚满二酮(0.60mmol,0.088g)溶于12mL甲醇和甲苯(1/2,v/v)的混合溶液中,并滴加35μL的哌啶,持续搅拌(700rpm)加热回流19h,通过TLC确认反应完成后,将冷却至室温的混合物过滤,用冷乙醇,乙腈洗涤得到目标红色固体化合物TDTI(0.054g,38.1%)。
1H NMR(600MHz,CDCl3)δ7.94(d,J=24.4Hz,3H),7.86(s,1H),7.77(s,2H),7.47(m,3H),7.30(d,J=17.0Hz,2H),7.21(s,1H),7.15(d,J=5.6Hz,4H),7.09(s,4H).13C NMR(600MHz,CDCl3)δ190.2,189.7,150.6,148.0,147.3,146.7,143.7,142.0,140.5,134.5,129.4,127.6,127.1,126.6,124.9,124.4,123.5,123.4,123.1,122.9,122.7.MS(ESI)calcd for C36H23NO2S2[M+H]+,566.1204;found566.1234.
实施例6
探针分子TDTI的合成:在装有磁力搅拌器的25mL三口瓶中,将TPA-TTA(0.35mmol,0.151g)和1,3-茚满二酮(0.60mmol,0.088g)溶于12mL甲醇和甲苯(1/2,v/v)的混合溶液中,并滴加35μL的哌啶,持续搅拌(750rpm)加热回流21h,通过TLC确认反应完成后,将冷却至室温的混合物过滤,用冷乙醇,乙腈洗涤得到目标红色固体化合物TDTI(0.081g,40.9%)。
1H NMR(600MHz,CDCl3)δ7.94(d,J=24.4Hz,3H),7.86(s,1H),7.77(s,2H),7.47(m,3H),7.30(d,J=17.0Hz,2H),7.21(s,1H),7.15(d,J=5.6Hz,4H),7.09(s,4H).13C NMR(600MHz,CDCl3)δ190.2,189.7,150.6,148.0,147.3,146.7,143.7,142.0,140.5,134.5,129.4,127.6,127.1,126.6,124.9,124.4,123.5,123.4,123.1,122.9,122.7.MS(ESI)calcd for C36H23NO2S2[M+H]+,566.1204;found566.1234.
实施例7
荧光探针分子TDTI光谱性能的研究:
1、荧光探针分子TDTI的溶剂化效应
D-π-A结构的分子一般都具有明显的溶剂变色效应,其光物理性质随着溶剂极性的改变而改变。为测试TDTI的溶剂化效应,对不同极性的溶剂体系中探针TDTI的光谱性质进行了研究。
研究结果表明:
1)在不同极性的溶剂(从甲苯到水)中,如图1(a),最大吸收分别在522nm(ε=4.21×104L/M·cm),532nm(ε=3.49×104L/M·cm),534nm(ε=1.36×104L/M·cm),即随着溶剂极性增加,最大紫外吸收下降并红移,且TDTI的最大吸收波长都在可见光范围内,这为损伤性较小的生物荧光成像提供了理论依据;
2)随着溶剂极性从正己烷到二氯甲烷的增加,可以看到其最大发射波长从593nm移动到691nm,同时,发射强度也明显下降,如图1(c);
3)近一步地,在不同比例的1,4-二氧六环和水的混合溶液中,当水比例增加时(溶剂极性增大),荧光发射逐渐红移,其强度也显著降低,如图1(b);上述结果均表明TDTI的光物理性质明显地依赖于溶剂极性,具有显著的溶剂变色效应,这归因于分子结构中从电子给体三苯胺单元到电子受体1,3-茚满二酮的分子内电荷转移。
2、TDTI的AIE效应
除了溶剂化效应外,TDTI还表现出聚集诱导发光(AIE)现象。其AIE性能在二甲基亚砜(DMSO)/甲苯混合物中进行了研究。
研究结果表明:
1)如图2(a)所示,TDTI在纯的DMSO中表现出非常弱的荧光发射,随着甲苯含量的不断增加,从0%增加到95%,TDTI的发射光谱逐渐蓝移,这可能是由于聚集体的溶液环境极性降低所致。此外,其荧光强度也明显增强,这可能归因于TDTI聚集体的形成限制了分子内的运动。上述结果初步表明,TDTI具有典型的AIE效应,与分子设计理念一致;
2)为了进一步验证TDTI的AIE性能,对TDTI在良溶剂DMSO以及不良溶剂水、甲苯的光学显微镜下的成像和在不同比例的DMSO/甲苯混合溶液中的荧光共振光散射进行了研究测定。从图2(b)可以看出,TDTI从DMSO到水、甲苯其形态逐渐聚集成不规则的团簇并依次增大;
3)荧光共振光散射结果(图2(c))表明,随着不良溶剂甲苯的比例增大,共振光散射强度也增加,这说明TDTI的粒径也在变大。上述结果共同揭示了TDTI在不良溶剂中聚集态的存在及其较强的荧光发射,即AIE性能;
4)在固体状态下,TDTI的荧光发射峰位于682nm,具有近红外荧光发射,如图2(d)。这进一步为生物体的高分辨,无损伤荧光成像提供了可能。
实施例8
探针分子TDTI对LD的特异性研究:考虑到LD的低极性、疏水环境,TDTI在疏水介质油酸中的荧光发射被测定,如图3(a),选取高极性的水作为对比,可以很明显地看到,在水中几乎没有荧光,而油酸中荧光强度急剧增强,并测得油酸中的量子产率为32.8%;另外,测定了DMPC和TAG(LD的两种主要成分)对TDTI荧光发射的影响,由图3(b),在PBS溶液中TDTI几乎没有荧光,同时加入40μg/mL的DMPC和TAG到PBS溶液中,可以看到明显增强的荧光;通过ChemBioDraw 14.0计算得到TDTI的logP值为9.41,这表明TDTI强的亲脂特征。综上结果可以看出:亲脂性的TDTI可能由于“相似相溶“作用会聚集在疏水的球状LD中并具有明显的荧光发射,从而作为一种靶向LD的探针。
为了进一步验证TDTI对LD的靶向能力,利用商业LD染料BODIPY493/503进行了共定位实验。如图4,与TDTI(15μM)和BODIPY 493/503(1μM)共孵育后的HeLa细胞,有许多荧光强度较强的LDs特征结构的圆点被观察到,并且商业染料BODIPY 493/503的绿色通道和TDTI的红色通道重叠性较好,Pearson共定位系数R达到了0.84。该结果证实了TDTI对LD很好的靶向能力。
实施例9
荧光探针分子TDTI对LD成像的应用研究:
1、TDTI对癌症的诊断及细胞中LD的动态追踪
1)探针作为生物材料用于长期监测活体中细胞器,光稳定性是一个重要的指标,因此首先对TDTI的光稳定性进行了研究。研究结果表明:TDTI(15μM)与HeLa细胞共孵育4.5h后,共聚焦激光在15min内连续扫描细胞30次,荧光强度几乎没有变化,这表明TDTI具有优异的光稳定性,是一种可用于监测脂代谢的理想生物探针;
2)为了证实TDTI用于癌症诊断的可能性,癌细胞(A549,HeLa,HEPG2)和正常细胞(TM3,MPC5,LO2)分别用TDTI(15μM)孵育4.5h,其余条件也均相同,细胞成像的结果与预期一致,癌细胞中呈现明亮的红色荧光点,而正常细胞中几乎没有荧光,如图5。这表明探针TDTI可用于癌细胞与正常细胞的区分;
3)另外,以油酸作为促进细胞中脂质体产生的刺激物,LO2细胞和HeLa细胞分别用50μM的油酸孵育2h后,再与TDTI(15μM)共孵育4.5h,未经油酸处理的两种细胞作为对照组。如图6所示,用油酸处理后的LO2细胞与HeLa细胞相比于对照组,红色荧光点的数量明显增多,荧光强度也更亮,这进一步说明了TDTI对LD的特异性靶向,并可用于监测细胞中LD的数量,对于LD相关疾病的诊断和生物医学研究有重要意义;
4)LD的动态运动与脂肪酸的代谢以及其他细胞器的相互作用密切相关,TDTI优异的LD特异性、高亮度和强的光稳定性表明其可能适合于监测LD的动态运动。随后,对TDTI(15μM)染色的HeLa细胞中LD的动态运动进行了监测。用不同伪彩标记LDs进行荧光成像,每隔2min记录一次,通过不同时间的图像叠加,可以清楚地观察到LDs的空间位移,如图7。这表明利用TDTI可以很好地监测活细胞中LD的形态特征及动态运动。
鉴于TDTI在细胞中对LD选择性成像优异的性能,对TDTI在活体中LD成像进行了研究。研究结果表明:选取三天龄左右的斑马鱼用含TDTI(15μM)的纯净水喂养5h后,观察到明亮的红色荧光几乎遍布斑马鱼全身,而作为对照组没有用TDTI处理的斑马鱼,其荧光通道几乎没有荧光呈现,如图8。上述成像结果表明TDTI可以对斑马鱼中的LD进行特异性成像。
实施例10
探针分子TDTI产生活性氧的能力及其对细胞光毒性的研究:
1、TDTI产生活性氧能力的研究
具有D-π-A结构AIE性能的荧光探针可作为潜在的光敏剂,同时用于生物成像和光动力治疗。因此,对TDTI在PBS溶液中产生活性氧的效率进行了初步研究。
考虑到TDTI在可见光区的强吸收,采用超低功率的白光(400-700nm,10mw cm-2)作为诱导活性氧产生的光源,商用活性氧捕获剂DCFH-DA(被活性氧氧化,荧光发射增强)来评估TDTI在PBS溶液中产生活性氧的效率。如图9所示,每隔10s光照一次,相比于DCFH-DA本身,DCFH-DA和TDTI(10μM)的混合溶液中,随着光照时间的增加,荧光强度也明显地增强,并且光照60s左右后其强度达到了平衡。而以抗坏血酸(1mM)作为自由基清除剂加入到上述DCFH-DA和TDTI的混合溶液中时,随着光照时间的增加,其荧光强度的变化明显减弱。此外,DCFH-DA和TDTI的混合溶液无白光照射时荧光非常微弱,光照60s后,其荧光急剧增强,且加入抗坏血酸后同样的光照60s,荧光仅有轻微的增加。上述现象均表明TDTI能够有效地产生自由基活性氧,这使它可能破坏肿瘤细胞的能量中心并杀死肿瘤细胞从而成为潜在的癌症治疗的光敏剂。
2、TDTI对细胞光毒性的研究
鉴于上述TDTI产生活性氧的能力,进一步通过MTT实验评估了TDTI对癌细胞HEPG2的光损伤效率。由图10可知,不同浓度的TDTI与HEPG2细胞在黑暗条件下孵育4.5h,TDTI对HEPG2细胞在浓度高达20μM时也几乎没有明显的细胞毒性。然而,在白光照射2h后,HEPG2细胞表现出明显的浓度依赖性的细胞毒性,TDTI的浓度为20μM时,其存活率仅为51%。该结果表明TDTI在光照射下可以有效地在细胞内产生活性氧,从而抑制细胞的生长存活。
Claims (9)
2.一种权利要求1所述的基于AIE性能的脂滴特异性荧光探针的制备方法,其特征在于,包括以下步骤:
步骤1:将4-(二苯基氨基)苯基硼酸、5-溴-2,2-联噻吩甲醛和四三苯基磷钯溶解在由1,4-二氧六环和碳酸钠水溶液组成的混合溶液中,于氮气氛围中持续搅拌加热回流,反应完成后,冷却至室温,过滤,收集得到的滤液,经过萃取、洗涤后,收集有机相,干燥、旋干,经柱色谱纯化得到化合物5-(4-(二苯基氨基)苯基)联噻吩-2-甲醛;
步骤2:将步骤1中得到的化合物5-(4-(二苯基氨基)苯基)联噻吩-2-甲醛和1,3-茚满二酮溶于由甲醇和甲苯组成的混合溶液中,滴加哌啶,持续搅拌加热回流,反应完成后,冷却至室温,过滤、洗涤得到目标固体化合物,即为所述的荧光探针。
3.根据权利要求2所属的一种基于AIE性能的脂滴特异性荧光探针的制备方法,其特征在于:所述步骤1中5-溴-2,2-联噻吩甲醛:4-(二苯基氨基)苯基硼酸:四三苯基磷钯的摩尔比为1:0.9~1.1:0.055;由1,4-二氧六环和碳酸钠水溶液组成的混合溶液中1,4-二氧六环和碳酸钠水溶液的体积比为3:1;碳酸钠水溶液的浓度为1.5-3mmol;每1mmol 5-溴-2,2-联噻吩甲醛使用混合溶液16mL。
4.根据权利要求2所属的一种基于AIE性能的脂滴特异性荧光探针的制备方法,其特征在于:所述步骤1中搅拌加热回流的搅拌转速为600~750rpm,加热回流时间为20~22h;萃取用二氯甲烷,三次;洗涤用饱和食盐水,两次;干燥用无水Na2(SO4);柱色谱纯化的展开剂为乙酸乙酯:石油醚=1:5,v/v。
5.根据权利要求2所属的一种基于AIE性能的脂滴特异性荧光探针的制备方法,其特征在于:所述步骤2中5-(4-(二苯基氨基)苯基)联噻吩-2-甲醛、1,3-茚满二酮和哌啶的摩尔比为1.5~3.5:6:3.5;由甲醇和甲苯组成的混合溶液中甲醇和甲苯的体积比为1:2;每1mmol 1,3-茚满二酮用混合溶液20mL。
6.根据权利要求2所属的一种基于AIE性能的脂滴特异性荧光探针的制备方法,其特征在于:所述步骤2中搅拌加热回流的搅拌转速为600~750rpm,加热回流时间为19~21h;洗涤用冷乙醇,乙腈反复洗涤。
7.一种权利要求1所述的基于AIE性能的脂滴特异性荧光探针的应用,其特征在于:用于制备动态追踪脂滴的试剂或识别癌细胞的试剂。
8.一种权利要求1所述的基于AIE性能的脂滴特异性荧光探针的应用,其特征在于:制备用于活体斑马鱼中脂滴特异性成像的试剂。
9.一种权利要求1所述的基于AIE性能的脂滴特异性荧光探针的应用,其特征在于:用于制备肿瘤细胞光动力治疗的试剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210541590.3A CN114907311A (zh) | 2022-05-17 | 2022-05-17 | 一种基于aie性能的脂滴特异性荧光探针及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210541590.3A CN114907311A (zh) | 2022-05-17 | 2022-05-17 | 一种基于aie性能的脂滴特异性荧光探针及制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114907311A true CN114907311A (zh) | 2022-08-16 |
Family
ID=82767831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210541590.3A Withdrawn CN114907311A (zh) | 2022-05-17 | 2022-05-17 | 一种基于aie性能的脂滴特异性荧光探针及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114907311A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116253722A (zh) * | 2023-02-15 | 2023-06-13 | 四川大学华西医院 | 一种高效产生单线态氧且能特异性靶向脂滴的咪唑类荧光探针及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112174839A (zh) * | 2020-11-05 | 2021-01-05 | 四川大学华西医院 | 一种脂滴特异性标记的荧光探针及其合成方法和应用 |
CN113845519A (zh) * | 2021-09-18 | 2021-12-28 | 山西大学 | 一种微环境敏感型荧光探针及其制备方法和应用 |
CN114031614A (zh) * | 2021-11-01 | 2022-02-11 | 吉林化工学院 | 一种双细胞器成像、细胞活力评估和光动力癌细胞消融的荧光探针及制备和应用 |
-
2022
- 2022-05-17 CN CN202210541590.3A patent/CN114907311A/zh not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112174839A (zh) * | 2020-11-05 | 2021-01-05 | 四川大学华西医院 | 一种脂滴特异性标记的荧光探针及其合成方法和应用 |
CN113845519A (zh) * | 2021-09-18 | 2021-12-28 | 山西大学 | 一种微环境敏感型荧光探针及其制备方法和应用 |
CN114031614A (zh) * | 2021-11-01 | 2022-02-11 | 吉林化工学院 | 一种双细胞器成像、细胞活力评估和光动力癌细胞消融的荧光探针及制备和应用 |
Non-Patent Citations (3)
Title |
---|
CHUNXUAN QI ET AL.: ""Study of Red-Emission Piezochromic Materials Based on Triphenylamine"", 《CHEMPLUSCHEM》, vol. 81, no. 7, pages 1 * |
MING-YU WU ET AL.: ""A near-infrared AIE probe for super-resolution imaging and nuclear lipid droplet dynamic study"", 《MATER. CHEM. FRONT.》, vol. 5, pages 3043 - 3049 * |
YANPENG DAI ET AL.: ""Multifunctional aggregation-induced emission nanoparticle for high-fidelity imaging of lipid droplets in living cells and its application in photodynamic therapy"", 《CHEMICAL ENGINEERING JOURNAL》, pages 1 - 13 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116253722A (zh) * | 2023-02-15 | 2023-06-13 | 四川大学华西医院 | 一种高效产生单线态氧且能特异性靶向脂滴的咪唑类荧光探针及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018108070A1 (en) | Luminogens for biological applications | |
CN111263751A (zh) | 具有聚集诱导发光特性的水溶性化合物 | |
CN111978313B (zh) | 具备聚集诱导发光性质的多模态光诊疗剂及其制备与应用 | |
CN110407736B (zh) | 具有强双光子吸收的近红外化合物的制备及应用 | |
CN108069908B (zh) | 荧光探针及其应用 | |
CN111303139B (zh) | 具有聚集诱导发光性能的化合物及其制备方法和应用 | |
CN114213419B (zh) | 一种兼具荧光成像和i型光动力/光热杀伤癌细胞活性的荧光探针及其制备方法和应用 | |
CN107722055B (zh) | 一种低功率白光驱动的线粒体靶向荧光探针光敏剂及其合成方法及应用 | |
CN102146284A (zh) | 一种比率型荧光探针及其应用 | |
CN110845418B (zh) | 基于醌式吸电子基团型的化合物及其制备方法和应用 | |
Ma et al. | Enhanced singlet oxygen generation of a soft salt through efficient energy transfer between two ionic metal complexes | |
Kong et al. | A two-photon AIE fluorophore as a photosensitizer for highly efficient mitochondria-targeted photodynamic therapy | |
CN114031614A (zh) | 一种双细胞器成像、细胞活力评估和光动力癌细胞消融的荧光探针及制备和应用 | |
Wang et al. | Near-infrared vinyl-containing aza-BODIPY nanoparticles as photosensitizer for phototherapy | |
Sun et al. | Near-infrared dual-functional AIEgens for lipid droplets imaging in multispecies and photodynamic therapy | |
Wang et al. | Precise design and synthesis of an AIE fluorophore with near-infrared emission for cellular bioimaging | |
CN114907311A (zh) | 一种基于aie性能的脂滴特异性荧光探针及制备方法和应用 | |
Sheng et al. | Hybridization of triphenylamine to BODIPY dyes at the 3, 5, 8-positions: A facile strategy to construct near infra-red aggregation-induced emission luminogens with intramolecular charge transfer for cellular imaging | |
CN114195774A (zh) | 一种具有次氯酸激活荧光和线粒体靶向功能的光敏剂及其制备方法和应用 | |
CN113454067B (zh) | 用于单线态氧生成与癌症消融的荧光探针 | |
CN108774249B (zh) | 噁嗪类化合物及其应用 | |
CN108358972B (zh) | 邻菲罗啉钌配合物类光敏染料及其制备方法和用途 | |
Dixit et al. | Synthesis and photophysical properties of near infra-red absorbing BODIPy derivatives and their nanoaggregates | |
CN113024586B (zh) | 一种细胞膜靶向的bodipy型有机光敏剂及应用 | |
CN110498809B (zh) | 基于酰腙配体类的有机硼化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220816 |
|
WW01 | Invention patent application withdrawn after publication |